Amicus Therapeutics, Inc.
NASDAQ: FOLD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bradley L. Campbell
- Employees
- 499
- Headquarters
- Philadelphia, United States
- IPO year
- 2007
- Market cap
- $4.5B
- Website
- https://amicusrx.com
Loading FOLD…
Loading profile data…Frequently asked questions about FOLD
What does Amicus Therapeutics, Inc. (FOLD) do?
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenabl...
Where does FOLD trade?
Amicus Therapeutics, Inc. (FOLD) trades on the NASDAQ Global Market.
What sector is FOLD in?
Amicus Therapeutics, Inc. (FOLD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Amicus Therapeutics, Inc.?
Bradley L. Campbell is the chief executive officer of Amicus Therapeutics, Inc. (FOLD).
Where is Amicus Therapeutics, Inc. headquartered?
Amicus Therapeutics, Inc. is headquartered in United States.
Does FOLD pay a dividend?
Amicus Therapeutics, Inc. (FOLD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FOLD go public?
Amicus Therapeutics, Inc. (FOLD) completed its initial public offering in 2007.